Induction and Expansion of T Cell Repertoire Using Growth Hormone and Vaccination in HIV-1 Infected Patients
- Conditions
- HIV Infections
- Interventions
- Biological: recombinant human Growth HormoneBiological: VaccinationDrug: HAART
- Registration Number
- NCT00287677
- Lead Sponsor
- Germans Trias i Pujol Hospital
- Brief Summary
Concomitant administration of recombinant human growth hormone (rhGH) may boost the expansion of immune reconstitution and broaden specific T cell responses not achievable by vaccination alone. The main objective of that study is to test the validity of this hypothesis with vaccines which are routinely administered to HIV-1 patients(tetanus toxoid and hepatitis A virus vaccines) in order to, if proven of value, use this strategy of HIV vaccination in the near future. This is a pilot, randomized, clinical open label study aimed to investigate thymic functionality and the HIV-specific responses after administration of rhGH in HIV-1 infected patients in highly active antiretroviral therapy (HAART) regimen.
- Detailed Description
The purpose of a therapeutic vaccine is to control, induce and expand humoral and cellular immune responses capable to control HIV infection. The administration of a conventional vaccine results in the expansion of peripheral clones. Concomitant administration of rhGH may boost this expansion and reconstitute specific T cell responses not achievable by vaccination alone. In this study we want to investigate whether the administration of rhGH expand T cell repertoire and whether there is an increase in the specific cellular responses to HIV-1 and recall antigens and, lately, whether this responses can be further amplified after immunization with tetanus toxoid and hepatitis A vaccines. This Hypothesis will be evaluated by the measurement of thymic volume, the expansion of naïve, memory and effector cell subsets, analysis of thymic emigrants (TRECs) before, during and after rhGH administration and vaccination. Moreover, T cell receptor rearrangement, specific antibodies and cellular responses to antigenic peptides will be determined.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 33
- HIV-1 asymptomatic patients in HAART regimen (> 6 months)
- Viral load < 50 copies/ml
- Number CD4 cells > 250 cells/mm3
- Non responders to vaccination (tetanus toxoid and/or Hepatitis A virus)
- Well-disposition to rhGh daily administration (6 months of treatment)
- AIDS outbreak
- Allergy or hyperreactivity to rhGH or vaccines
- Diabetes Mellitus
- Renal, hepatic, pancreatic disorders
- Chronic diseases
- Dementia
- Pregnancy
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description A recombinant human Growth Hormone growth hormone + vaccination + HAART A Vaccination growth hormone + vaccination + HAART A HAART growth hormone + vaccination + HAART B recombinant human Growth Hormone growth hormone + HAART B HAART growth hormone + HAART C Vaccination vaccination + HAART C HAART vaccination + HAART D Vaccination control healthy HIV negative + vaccination
- Primary Outcome Measures
Name Time Method Proportion of patients HIV+ that recover the immunospecific responses against tetanus toxoid and Hepatitis A at 24 weeks of rhGH administration (time of treatment interruption). from 24 weeks post rhGH administration
- Secondary Outcome Measures
Name Time Method The rhGH activates the thymic function. from one year post rhGH administration This effect is lasting once the rhGH administration is interrupted. from at least one year since the last rhGH administration
Trial Locations
- Locations (2)
Germans Trias i Pujol Hospital
🇪🇸Badalona, Barcelona, Spain
Hospital Clinic de Barcelona
🇪🇸Barcelona, Spain